Respiratory Drugs Market Global Briefing 2018

Starting Price : $ 1000.00 | Pages : 34 | Published : January 2018 | SKU CODE : 2776 | Format :

Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral®, Coldrex® and Lemsip®. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing.

North America was the largest region in the respiratory diseases drugs market in 2017, accounting for around 48% market share. This was mainly due to high number of patients with respiratory diseases, more people covered under medical insurance programs and higher pricing of medications in the USA. Asia Pacific was the second largest region accounting for around 19% market share. This can be attributed to the rise in tobacco smoking and pollution levels in Asian countries such as China, India and Japan, thus leading to more number of patients with respiratory diseases. China was the largest, while Japan was the third largest tobacco consuming country in the world. Africa was the smallest region accounting for around 2% market share.  
Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products – The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief.  However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products. For instance, in March 2017, pharmaceutical companies Acura Pharmaceuticals Inc. and MainPointe Pharmaceuticals LLC entered into an agreement, enabling MainPointe Pharmaceuticals LLC to market NEXAFED and NEXAFED Sinus products in the US and Canada. These drugs utilize tamper-resistant PSE formulation to prevent the illicit production of methamphetamine.

Companies Covered: GlaxosmithKline Plc., AstraZeneca Plc., Merck & Co., Novartis AG, Johnson & Johnson, Gilead, Bayer AG, Boehringer Ingelheim GmbH, Teva Pharmaceuticals, Pfizer Inc.

Market Segments Included: Respiratory Drugs, Anti-Asthmatics And COPD Drugs, Decongestants, Cough And Cold Preparations.

Over 1000 Biologics Under Development Will Drive The Biologics Market To 10% Yearly Growth

Public Policy Restrains Blood Glucose Test Strips Market Growth

The Leading Players In The Cardiovascular Devices Market Are Innovating To Stay Ahead

India Is The World’s Fastest-Growing Market For In-Vitro Diagnostics

Lower Average Prices Will Affect Global Market For Blood Glucose Test Strips

Neurology Devices Are Replacing Drugs As First Treatment Preference

Eastern Europe Is The Fastest-Growing Region For The Cancer Drugs Market

Increased Pet Ownership Drives Veterinary Services Market Growth

Veterinary Services Global Market Report 2018

View Report

Blood Glucose Test Strips Global Market Report 2018

View Report

Nephrology And Urology Devices Market Global Briefing 2018

View Report

Neurology Devices Market Global Briefing 2018

View Report

ENT Devices Market Global Briefing 2018

View Report

Orthopedic Devices Market Global Briefing 2018

View Report

Wound Care Devices Market Global Briefing 2018

View Report

Diabetes Care Devices Market Global Briefing 2018

View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)